254 related articles for article (PubMed ID: 36485135)
1. Antibodies and bispecifics for multiple myeloma: effective effector therapy.
Cipkar C; Chen C; Trudel S
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):163-172. PubMed ID: 36485135
[TBL] [Abstract][Full Text] [Related]
2. Bispecifics, trispecifics, and other novel immune treatments in myeloma.
Lancman G; Richter J; Chari A
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):264-271. PubMed ID: 33275733
[TBL] [Abstract][Full Text] [Related]
3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Based Treatment Approaches in Multiple Myeloma.
Hosoya H; Sidana S
Curr Hematol Malig Rep; 2021 Apr; 16(2):183-191. PubMed ID: 33730360
[TBL] [Abstract][Full Text] [Related]
5. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
De Luca F; Allegra A; Di Chio C; Previti S; ZappalĂ M; Ettari R
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
[TBL] [Abstract][Full Text] [Related]
7. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
8. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
10. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
11. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
Parrondo RD; Ailawadhi S; Cerchione C
Front Oncol; 2024; 14():1394048. PubMed ID: 38660139
[TBL] [Abstract][Full Text] [Related]
13. [Bispecific antibodies in multiple myeloma].
Escure G; Manier S
Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
[TBL] [Abstract][Full Text] [Related]
14. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
Braunstein M; Weltz J; Davies F
Expert Rev Hematol; 2021 Apr; 14(4):377-389. PubMed ID: 33769179
[TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
16. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Ray U; Orlowski RZ
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111346
[TBL] [Abstract][Full Text] [Related]
18. Belantamab Mafodotin: First Approval.
Markham A
Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
[TBL] [Abstract][Full Text] [Related]
19. New and emerging pharmacotherapies for the management of multiple myeloma.
Moore DC; Oxencis CJ; Shank BR
Am J Health Syst Pharm; 2022 Jul; 79(14):1137-1145. PubMed ID: 35333922
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies as an addition to current myeloma therapy strategies.
Jullien M; Touzeau C; Moreau P
Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]